Abstract. This study was designed to investigate the role of protein kinase C (PKC) and extracellular signal-regulated kinase 1/2 (ERK1/2) signaling in tamoxifen (TAM)-induced apoptosis and drug resistance in human breast cancer cells. Drug-sensitive, or estrogen receptor (ER)-positive human breast carcinoma cells (MCF-7) and the multi-drug-resistant variant (ER-negative) MCF-7/ADR cells were treated with doses of TAM for various periods of time. Cell viability and apoptosis were assessed using cell counting, DNA fragmentation and flow cytometric analysis. We found that TAM administration caused a significant increase in apoptosis of MCF-7 cells but not MCF-7/ADR cells. Western blot analysis revealed enhanced expression of PKCδ but decreased expression of PKCα in ER-positive MCF-7 cells; while ER-negative MCF-7/ADR cells had decreased levels of PKCδ and increased levels of PKCα. Interestingly, we observed that in MCF-7 cells, TAM stimulated apoptosis by promoting rapid activation of PKCδ, antagonizing downstream signaling of ERK phosphorylation; while in MCF-7/ADR cells, TAM upregulated PKCα, which promoted ERK phosphorylation. These results suggest that PKCδ enhances apoptosis in TAM-treated MCF-7 cells by antagonizing ERK phosphorylation; while the PKCα pathway plays an important role in TAM-induced drug resistance by activating ERK signaling in MCF-7/ADR cells. The combination of TAM with PKCα and ERK inhibitors could promote TAM-induced apoptosis in breast cancer cells.
Introduction
Breast cancer is a common malignancy in females and the second cause of death from cancer in women today (1) . Treatment for breast cancer includes surgery, chemotherapy, radiotherapy and endocrine therapy. Tamoxifen (TAM), an antagonist of the estrogen receptor (ER), is a selective ER modulator (SERM). TAM is a front-line endocrine therapeutic drug for ER-positive breast cancers. Results from TAM therapy showed a 40-50% reduction in the risk of cancer recurrence and cancer mortality (2) . Recently, TAM has been demonstrated to be effective for some ER-negative breast cancers, as well as other types of cancers, including gliomas. These data suggest that TAM may also be implicated in ER-independent antitumor mechanisms (3, 4) . Of note, some advanced breast cancers that initially respond well to TAM eventually become refractory to treatment (5) (6) (7) (8) (9) . Thus, the traditional mechanism of TAM action through the ER is challenged, and other noncanonical pathways need to be explored.
Protein kinase C (PKC), a family of serine/threonine kinases, is involved in many important cellular functions, including cell proliferation, migration, differentiation, and apoptosis (10) (11) (12) . Twelve PKC isoforms have been discovered in various cell types, including conventional PKCs (cPKCα, βI/βII and γ), novel PKCs (nPKCδ, ε, η), and atypical PKCs (aPKCζ) (13, 14) . The expression of PKCα, δ, ε, η, γ, μ, and ζ has been detected in MCF-7 cells (15, 16) ; PKCα is a marker for anti-estrogen resistance and is involved in the growth of TAM-resistant human breast cancer cells (17, 18) . Overexpression of PKCα stimulates the proliferation of MCF-7 cells and C6 glioma cells (14, 19) . PKCδ controls cellular proliferation, differentiation, migration and apoptosis in various cell types (13, 21, 22) , representing the predominant isoform expressed in MCF-7 cells (20) . Studies of PKCδ in estrogen-responsive tissues have been contradictory. PKCδ increased proliferative and survival capacities in an immortal- ized mammary cell line (23) . Estrogen has been reported to stimulate the expression of PKCδ in the corpus luteum (24) , but to downregulate the expression of PKCδ in MCF-7 cells (20) . A small molecule PKCδ inhibitor or a dominant-negative PKCδ mutant impaired phorbol ester-induced cell arrest in the G1 phase in SKRB-3 breast cancer cells (25) . Alternatively, some studies have suggested that PKCδ could act as a positive regulator of growth in tumor-derived mammary cells, potentially through activating the mitogenic Ras/extracellular signal-regulated kinase 1/2 (ERK1/2) pathway (26, 27) . A prosurvival role for PKCδ in breast cancer cells has also been reported (22, 28) . The mitogen-activated protein kinase (MAPK) superfamily consists of four major sets of kinases: the extracellular-receptor kinases (ERK), c-jun N-terminal or stress-activated protein kinases (JNK/SAPK), ERK5/big MAP kinase 1 (BMK1), and the p38 protein kinases (29) . Growth factor-regulated gene transcription and cell proliferation are blocked in mammalian cells when MAPK activity is inhibited (30) (31) (32) , indicating that MAPKs are necessary for cell growth. Inhibition of ERK signaling using a MEK inhibitor, PD98059, induced apoptosis in MCF-7 cells (33, 34) . ERK activation was inversely correlated with apoptosis (35, 36) . Activation of ERK by TAM has previously been shown in HeLa cells (37) and human endometrial cancer cells (38) . Recently, TAM was shown to activate ERK in ER-positive MCF-7 and T47D cells but not in ER-negative MDA-MB-231 cells (39) . Katayama et al (40) suggested that blockade of the MEK-ERK-RSK pathway suppressed cell surface P-glycoprotein expression by promoting its degradation, leading to decreased multidrug resistance (MDR).
Role of PKC-ERK signaling in tamoxifen-induced apoptosis and tamoxifen resistance in human breast cancer cells
Drug resistance is a major clinical limitation for the successful management of breast cancers (42) (43) (44) (45) . In the present study, we investigated the mechanisms of TAM-induced apoptosis and drug resistance using MCF-7 cells and its multidrug-resistant variant, MCF-7/ADR cells.
Materials and methods
Reagents. RPMI-1640 and phenol red-free RPMI-1640 were purchased from Gibco-BRL (Grand Island, NY, USA). TAM, rottlerin, and PD98086 were obtained from Sigma-Aldrich (St. Louis, MO), dissolved in dimethyl sulfoxide (DMSO) at 10 mM and stored at -20˚C. Gö6976 (Calbiochem, San Diego, CA, USA) was dissolved in DMSO at 1 mM and stored at -20˚C. Rabbit polyclonal antibodies specific for phospho-PKCα, PKCα, PKCδ, ERK, and β-actin and a mouse monoclonal antibody specific for phospho-ERK were obtained from Cell Signaling Technology (Beverly, MA, USA); the rabbit polyclonal phospho-PKCδ antibody was from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA); and HRP-conjugated secondary antibodies (anti-mouse and antirabbit) were from QED, Biovision, Inc. (Hercules, CA, USA). The enhanced chemiluminescence (ECL) kit was purchased from GE Healthcare (USA).
Cell lines and cell cultures.
Human breast carcinoma MCF-7 cells and their multidrug resistant variant, MCF-7/ADR cells, were kindly provided by Professor Wenlin Huang (Sun Yat-Sen University, China). The cells were maintained in RPMI-1640 supplemented with 10% fetal bovine serum (FBS), 100 U/ml of penicillin, and 100 µg/ml of streptomycin under standard incubation conditions (humidified atmosphere, 95% air, 5% CO 2 , 37˚C). Cells were passaged every 3 days at a ratio of 1:3 using 0.125% trypsin-0.02% EDTA. For experiments, cells in the third to fourth passage were used. Cells of 5x10 5 /90-mm dish or 10 5 cells/60-mm dish were cultured in phenol red-free RPMI-1640 supplemented with 10% dextran-coated charcoal (DCC)-FBS according to the protocol of Migliaccio et al (46) . Following 24 h culture in estrogen-depleted medium, the cells were starved overnight with phenol red-free RPMI-1640 containing 1% DCC-FBS, followed by additions of TAM, rottlerin, Gö6976 or PD98059 at the indicated concentrations. After washing with phosphate-buffered saline (PBS), the cells were collected at the time points indicated.
Cell death analysis. To evaluate the effects of TAM on cancer cell death, cells were plated at a density of 5x10 5 cells/ml in 60-mm cell culture plates. Following starvation with phenol redfree RPMI-1640 containing 1% DCC-FCS for 24 h, cells were treated with various concentrations (1, 5, 10 or 20 µM) of TAM at the indicated time periods (1, 3, 6, 12 and 24 h). Thereafter, cells were trypsinized with trypsin-EDTA, stained with trypan blue solution (0.04% w/v), and counted using a hemocytometer. The number of dead or live cells was calculated in each sample, and vehicle controls (0.1% DMSO) were included in each experiment. Each experiment was performed in triplicate.
Detection of apoptotic cells. MCF-7 and MCF-7/ADR cells were grown in 6-well plates at a density of 10,000/well. After treatment with 10 µM of TAM for 24 h, the cells were fixed in 4% paraformaldehyde for 15 min at room temperature, permealized with 0.1% Triton X-100 (Sigma-Aldrich) for 30 min, rinsed with PBS and incubated for 5 min at room temperature with 0.01% DAPI stain (Sigma-Aldrich). Excessive stain was removed by washing the cells with PBS. Nuclei were visualized using a Leica fluorescence microscope. The cells with condensed and/ or fragmented nuclei were scored as apoptotic cells.
DNA fragmentation (DNA ladders).
To confirm TAM-induced apoptosis, DNA fragmentation was performed in TAM-treated cells as previously described (47) . In brief, cells that were treated with TAM for different periods of time were collected and digested in 500 µl of lysis buffer (10 mM Tris, pH 7.5; 25 mM EDTA; 1% SDS; 100 mM NaCl) for 15 min at room temperature. Lysed cells were then treated with 1 mg/ml of proteinase K (final concentration 100 µg/ml), and incubated at 56˚C for 30 min. DNA was extracted twice with phenol/chloroform/isoamyl alcohol (25:24:1) and chloroform prior to 1.5% agarose electrophoresis. DNA ladders in the gel were detected using GoldView staining (SBS Genetech, China) under UV illumination.
Quantification of apoptosis by flow cytometry. Cells were treated with 5, 10 or 20 µM of TAM or 0.1% DMSO as a control for 24 h. The cells were then harvested using trypsin-EDTA and were fixed in 70% cold ethanol overnight. The cells were subsequently treated with propidium iodide (50 mg/ml) and RNase (20 mg/ml) for 15 min and analyzed using a flow cytometer (Beckman Coulter) equipped with an air-cooled argon ion laser emitting at a wavelength of 488 nm at 15 mW. DNA histograms were assessed using the Beckman Coulter cytometry software from a minimum of 10,000 events/sample. To detect the effect of signaling inhibitors, cells were pretreated with 100 nM of Gö6976, 10 µM of rottlerin, or 20 µM of PD98059 for 1 h prior to treatment with or without 20 µM TAM for 24 h and harvested for flow cytometric analysis of apoptosis. All experiments were performed in triplicate.
Western blot analysis. Western blot analyses were performed as previously described (48) . In brief, protein extracts were obtained by lysing 5x10 6 cells in buffer A (20 mM HEPES, pH 7.4, 2 mM EDTA, 50 mM β-glycerophosphate, 1 mM dithiothreitol, 1 mM Na 3 VO 4 , 1% Triton, 10% glycerol) supplemented with protease inhibitors (4%) for 15 min on ice followed by sonication for 10 sec. Protein concentration was determined using the Bio-Rad DC protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA). Samples (60 µg) were denatured for 10 min in boiling water, followed by electrophoresis on 12% SDS-polyacrylamide gels and transferred onto nitrocellulose membranes (Pall Corporation, Ann Arbor, MI, USA) using electroblotting. Membranes were probed with antibodies as indicated (non-specific binding was blocked by incubation in TBS with 5% non-fat dry milk), followed by incubation with HRP-conjugated rabbit or mouse secondary antibodies. Detection was performed using enhanced chemiluminescence (Amersham) on Hyperfilm (Fuji, Japan) according to the manufacturer's instructions. The same blots were subsequently stripped and re-blotted with corresponding pan antibodies, and membranes were re-probed with a β-actin antibody as the loading control. For quantification, band intensities were quantified using GeneSnap (SynGene, Cambridge, UK) software and normalized to the corresponding total ERK or β-actin levels.
Data analyses. Each experiment was performed in triplicate, and the data were expressed as mean ± SD. Statistical analyses were performed utilizing the SPSS 11.5 software. Student's t-test and ANOVA were used in this study. Differences were considered significant when the P-values were <0.05. Fig. 1 , the number of dead MCF-7 cells increased in a time-and dose-dependent manner in the presence of TAM (Fig. 1A) . Treatment with 10 µM of TAM for 24 h resulted in a 49% of cell death in MCF-7 cells, but only ~15% of cells were dead in TAM-treated MCF-7/ADR cells (Fig. 1B) . The proportion of dead cells was nearly 100% in MCF-7 cells following treatment with 20 µM TAM (Fig. 1A) ; while the dead cell proportion was only 35% in MCF-7/ADR cells (Fig. 1B ). These data demonstrate that MCF-7 cells are susceptible to cell death induced by TAM, with the IC 50 of TAM in MCF-7 cells at approximately 10 µM; while MCF-7/ADR cells are resistant to TAM.
Results

TAM induces cell death in MCF-
TAM induces cell death in breast cancer cells via apoptosis.
Since cell death includes necrosis and apoptosis (49), we examined whether TAM induced cell death breast cancer via an apoptotic pathway. Multiple nucleosome fragments, DNA gel electrophoresis and flow cytometry were performed in TAM-treated MCF-7 and MCF-7/ADR cells. As shown in Fig 2A, typical apoptotic bodies were observed in MCF-7 cells treated with 10 µM of TAM for 24 h, while few apoptotic bodies appeared in the MCF-7/ADR cells. To further confirm apoptosis in these cells, genomic DNA was extracted from TAM-treated cells and was subjected to 1.5% agarose gel electrophoresis. As shown in Fig. 2B , DNA fragmentation became apparent in MCF-7 cells in response to 10 µM of TAM exposure, with ~65% of MCF-7 cells undergoing apoptosis ( Fig. 2B and C) . In addition, DNA fragmentation increased in a dose-dependent manner (Fig. 2B) . When cells were treated with 10 µM TAM for 12 to 72 h, DNA ladders were visible in MCF-7 cells, and the ladders gradually increased in a timedependent manner and peaked at 72 h (Fig. 2B) . Interestingly, no DNA fragmentation was detected in TAM-treated MCF-7/ ADR cells, except for the positive control cells (Fig. 2B) , and the percentage of apoptotic cells in MCF-7/ADR cells was significantly lower compared to that in MCF-7 cells (Fig. 2C-D) . These results suggest that TAM-induced cell death in breast cancer is predominantly due to apoptosis, and MCF-7/ADR cells are resistant to TAM. (Fig. 3A-D) (P<0.05) . Interestingly, TAM induced a rapid activation of PKCδ in MCF-7 cells in a time-dependent manner with the peak PKCδ activation detected at 60 min ( Fig. 3C and D) . Conversely, TAM stimulated PKCα phosphorylation in MCF-7 cells at 10 min, which was maintained up to 15 min. The phosphorylation level of PKCα began to decrease from 30 to 60 min, although the level of PKCα at these time points was still much higher compared to that in the vehicle control (P<0.05). In MCF-7/ADR cells, the basal level of PKCα phosphorylation was high, TAM treatment did not further alter their phosphorylation (Fig. 3A and B) .
Differential expression and phosphorylation of PKCα, PKCδ, and ERK in MCF-7 and MCF-7/ADR cells treated with
To assess the relationship between the PKC and MAPK families in breast cancer cells, we investigated ERK expression and its activation. As shown in Fig. 3E and F, p-ERK1/2 started to increase 10 min following TAM exposure in MCF-7/ ADR cells, and gradually increased in a time-dependent manner. However, in MCF-7 cells, ERK was only slightly activated at 30 min, with prominent phosphorylation of ERK1/2 observed at 60 min following TAM treatment. These data suggest that TAM-induced apoptosis in MCF-7 cells may be mediated through activation of PKCα, PKCδ and ERK; while the PKCα-ERK pathway promotes drug resistance in MCF-7/ ADR cells.
Impact of specific inhibitors of PKCα, PKCδ and ERK on TAM-treated MCF-7 and MCF-7/ADR cells.
To determine how PKC and ERK could promote both TAM-induced apoptosis and resistance, we utilized PKC and ERK inhibitors. Cells were pretreated with specific signaling inhibitors (Gö6976, 100 nM; rottlerin, 10 µM; PD98059, 20 µM) for 1 h and were then exposed to 10 µM of TAM for 24 h prior to flow cytometric analyses. As shown in Fig. 4 , the PKCδ inhibitor, rottlerin, clearly reduced TAM-induced apoptosis. MCF-7 cells demonstrated a 10.3±3.1% reduction, and MCF-7/ADR cells showed a 5.1±2.0% decrease in apoptosis (P<0.05). Alternatively, we found that the PKCα/β isozyme pharmacological antagonist, Gö6976 and the MAP kinase inhibitor, PD98059 increased the rate of apoptosis in breast cancer cells. These inhibitors increased cell apoptosis by 20% and 13% in TAM-treated MCF-7 and MCF-7/ADR cells, respectively. These results suggest that PKCδ promotes TAM-induced apoptosis in MCF-7 cells, while PKCα and ERK protect breast cancer cells from death.
Effect of rottlerin and PD98059 on the expression and phosphorylation of PKCδ and ERK in TAM-treated MCF-7 cells.
To investigate the relationship between PKCδ and ERK, we further assessed the impact of rottlerin and PD98059 on PKCδ and ERK activation. MCF-7 cells were pretreated with 10 µM of rottlerin or 20 µM of PD98059 for 1 h followed by 10 µM of TAM for 30 or 60 min. As shown in Fig. 5 , rottlerin inhibited PKCδ phosphorylation and increased activation of ERK in TAM-treated MCF-7 cells. Alternatively, PD98059 inhibited ERK activation but had no effect on PKCδ phosphorylation. These results indicate that TAM-induced apoptosis in MCF-7 cells may be mediated via activation of PKCδ and the subsequent inhibition of ERK. . Differential expression and phosphorylation of PKC and ERK in MCF-7 and MCF-7/ADR cells. Cells were treated with or without 10 µM of TAM (VC, 0.1% DMSO) for various time points prior to lysis. Lysate of 60 µg from each sample was loaded onto 12% SDS gels. P-PKCα, P-PKCδ, and P-ERK were evaluated using western blot analysis. The same membrane was re-probed using PKCα, PKCδ and ERK following stripping. (A) PKCα expression and phosphorylation; and (B) the ratio of P-PKCα to that of total PKCα; (C) PKCδ expression and phosphorylation; and (D) the ratio of P-PKCδ to that of total PKCδ; (E) the expression and phosphorylation of ERK; and (F) the ratio of P-ERK to that of total ERK. Data are representatives of three independent experiments (mean ± SD). 
Effect of Gö6976 and PD98059 on the expression and phosphorylation of PKCα and ERK in TAM-treated MCF-7/ADR cells.
As demonstrated by flow cytometry, both Gö6976 and PD98059 enhanced the TAM-induced apoptosis in MCF-7/ ADR cells. We then determined how the expression and phosphorylation of PKC and ERK were regulated. We pretreated the MCF-7/ADR cells with or without 100 nM Gö6976 or 20 µM PD98059 for 1 h followed by 10 µM TAM exposure for 15 min. As shown in Fig. 6 , both Gö6976 and PD98059 inhibited TAM-induced ERK phosphorylation in MCF-7/ADR cells; however, PD98059 had no effect on PKCα activity. We therefore, hypothesize that ERK may act downstream of PKCα, cooperating together on TAM resistance in MCF-7/ADR cells.
Discussion
Growing evidence on the mechanism of TAM-induced cancer inhibition have led to the discovery of many signaling intermediates that may play critical roles in this process (50) . However, mechanisms underlying TAM-induced apoptosis and TAM resistance are still not completely understood. In the present study, we determined for the first time that TAM was involved in both apoptotic and anti-apoptotic signaling pathways in breast cancer cells. We found that PKCδ phosphorylation participated in TAM-induced apoptosis in MCF-7 cells by antagonizing downstream ERK signaling; while in MCF-7/ ADR cells, PKCα activated downstream ERK signaling and promoted drug resistance. Our results also revealed that Gö6976 and PD98059 could promote TAM-induced apoptosis in these cells.
In breast cancer, TAM results in either a cytostatic end point (cell growth arrest) at nanomolar (nM) or a cytotoxic end point (cell death leading to tumor shrinkage and regression in vivo) at micromolar (µM) concentrations (41) . We observed that TAM-induced cell death in MCF-7 cells was dose-and time-dependent. However, in MCF-7/ADR cells, even with high concentrations and long term exposure of TAM (10 µM, for 72 h), the rate of apoptosis was still very low, implying that MCF-7/ADR cells were resistant to TAM.
There are many contradictory data on the pro-apoptotic or pro-survival effects of PKCδ (16, 22, 25) . PKCδ has been reported to protect RAW264.7 macrophages from nitric oxideinduced apoptosis (51) . PKCδ increased mammary tumor cell growth and metastasis by activation of the Ras/ERK1/2 pathway (27) . In this study, TAM stimulated PKCδ activation in MCF-7 cells. The PKCδ specific inhibitor, rottlerin, prevented TAM-induced apoptosis by inhibiting PKCδ phosphorylation and elevating p-ERK; while the ERK inhibitor, PD98059 increased apoptosis, but had no effect on PKCδ activation in these cells, indicating that ERK is the downstream mediator of PKCδ. Our results are different from a report by Greco et al (52) in which they suggest that PKCδ/ε mediated the PKC/Akt-dependent phosphorylation of ERK in MCF-7 cells, and led to cell proliferation. It is therefore possible that the activation of PKCδ by various factors may lead to divergent signaling pathways.
PKCα is associated with cell proliferation in various cell types (53) (54) (55) . Several lines of evidence indicate that inhibition of PKCα is sufficient to induce apoptosis, suggesting that PKCα functions to suppress apoptosis in some cells (56, 57) . Overexpression of PKCα has been reported to promote the progression of breast cancer and reduce the expression of ER in MCF-7 cells (58) . Interestingly, we observed that p-PKCα was overexpressed in the ER-negative MCF-7/ADR cells; it is possible that the high level of endogenous PKCα in MCF-7/ADR cells contributes to TAM resistance. In the present study, we also found that TAM promoted ERK activation in MCF-7/ADR cells, and both Gö6976 and PD98059 enhanced TAM-induced apoptosis by inhibiting ERK phosphorylation, however, these inhibitors did not alter PKCα activation, indicating that ERK was the downstream mediator of PKCα and participated in the drug resistance of MCF-7/ADR cells. These results are in accordance with a previous study suggesting that PKC counteracts apoptosis by acting on downstream effectors (the MAPK pathway) in Jurkat T cells (59, 60) . Lin et al (61) also found that MAPK activation promoted β-estradiol-induced breast carcinoma cell proliferation. Conversely, Fujii et al (25) reported that the antineoplaston A10 arrested SKBR-3 cells in the G1 phase via PKCα and MAPK; and Wu and Huang (62) reported that PKCα is specifically required for TPA-induced ERK (MAPK) signaling, leading to inhibition of HepG2 cell growth.
In summary, our present results suggest that the PKC-ERK pathway plays an important role in mediating TAM-induced apoptosis as well as TAM resistance in breast cancer cells. PKCδ phosphorylation promoted TAM-induced apoptosis in MCF-7 cells by antagonizing ERK activation, while PKCα was involved in TAM resistance by activating downstream ERK signaling in MCF-7/ADR cells. Therefore, combinations of TAM with Gö6976 and PD98059 could promote TAM-induced apoptosis in breast cancer cells and reduce TAM resistance.
